C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?

Core Insights - C4 Therapeutics, Inc. is expected to report a quarterly loss of $0.37 per share, reflecting a year-over-year change of +49.3%, with revenues projected at $6.88 million, an increase of 158.7% from the previous year [1] Group 1: Stock Performance - C4 Therapeutics shares increased by 13.7% in the last trading session, closing at $7.38, with notable trading volume compared to typical sessions, and a total gain of 56.8% over the past four weeks [2] - The rise in stock price is linked to positive investor sentiment regarding the progress of C4's clinical pipeline, particularly the evaluation of cemsidomide (CFT7455) for multiple myeloma and non-Hodgkin lymphomas [3] Group 2: Earnings and Estimates - The consensus EPS estimate for C4 Therapeutics has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [5] - C4 Therapeutics holds a Zacks Rank of 3 (Hold), similar to Praxis Precision Medicines, which also has a consensus EPS estimate unchanged at -$2.39, representing a year-over-year change of +67.5% [5][6]